Evidera, a business unit of PPD, entered an exclusive collaboration agreement with Shin Nippon Biomedical Laboratories’ subsidiary, Clinical Study Support (CSS). This agreement will extend both organizations’ consulting and analytical capabilities and enable them to offer more clinical, real-world, and patient-centered research in Japan.
CSS is a clinical research organization (CRO) is based in Nagoya, Japan and offers post-market, real-world research services, including database studies, questionnaire development, and pharmacoeconomics.
Evidera and CSS will work to provide research services to global and Japan-based clients and undertake studies that include a Japanese component. Per the agreement, the two companies will establish a joint office in Japan to facilitate collaboration.
Tatsuya Isomura founder and CEO of CSS stated, “Our collaboration with Evidera allows us to support larger global projects that may benefit from our knowledge and expertise in Japanese-specific settings.”
Isomura added, “Our clients will gain access to global project management and operational resources that will enable larger and more complex research programs, as well as more robust evidence of product value and safety.”
These additional operational capabilities will include the design and implementation of real-world studies, epidemiological studies, qualitative and quantitative patient-centered research, clinical outcome assessment development and validation, patient recruitment for studies, and additional modeling services.
Additionally, the exclusive collaboration will see the two companies focus on the joint development of direct-to-electronic medical record (EMR) and EMR-enabled observational studies in Japan.
North Carolina-based PPD has work with Shin Nippon before. In 2015, the two companies formed a joint venture to provide clinical development services in Japan. In this agreement, Shin Nippon’s clinical research division and PPD’s clinical development operations team began providing services in Japan.
